

Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer

Information for the public

Published: 14 October 2020

www.nice.org.uk

Osimertinib (Tagrisso) is available on the NHS as a possible treatment for epidermal growth factor receptor (EGFR) T790M mutation-positive locally advanced or metastatic non-small-cell lung cancer (NSCLC) in adults. This is only if they have first had an EGFR tyrosine kinase inhibitor and their disease has got worse.

If you are not eligible for osimertinib but are already taking it, you should be able to continue until you and your doctor decide when best to stop.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about [making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The [NHS website](#) may be a good place to find out more.

These organisations can give you advice and support:

- [EGFR Positive UK](#), contact@egfrpositive.org.uk
- [British Lung Foundation](#), 03000 030 555
- [Cancer Research UK](#), 0808 800 4040
- [Macmillan Cancer Support](#), 0808 808 0000
- [Roy Castle Lung Cancer Foundation](#), 0333 323 7200.

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-3880-3